Yamada Y, Arai T, Sugawara S, Okato A, Kato M, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N:Impact of novel oncogenic pathways regulated by antitumor miR-451a in renal cell carcinoma. Cancer Sci 109: 1239-1253, 2018.
Yamada Y, Sugawara S, Arai T, Kojima S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N:Molecular pathogenesis of renal cell carcinoma: Impact of the anti-tumor miR-29 family on gene regulation. Int J Urol 25: 953-965, 2018.
Yamada Y, Arai T, Kojima S, Sugawara S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N:Regulation of antitumor miR-144-5p targets oncogenes: Direct regulation of syndecan-3 and its clinical significance. Cancer Sci, 2018.
Yamada Y, Arai T, Kojima S, Sugawara S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N:Anti-tumor roles of both strands of the miR-455 duplex: their targets SKA1 and SKA3 are involved in the pathogenesis of renal cell carcinoma. Oncotarget 9: 26638-58, 2018.
Arai T, Okato A, Yamada Y, Sugawara S, Kurozumi A, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N:Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC. Cancer Med, 2018.
Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K, Naya Y, Ichikawa T, Seki N:Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p. Mol Oncol, 2018.
Yamada Y, Nishikawa R, Kato M, Okato A, Arai T, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N:Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis. J Hum Genet 63: 195-205, 2018.
Kato T, Komiya A, Yuasa J, Kaga K, Kaga M, Kojima S, Naya Y, Isaka S.Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms. Oncol Lett. 15(2) 2669-72, 2018.
Kojima S, Goto Y, NayaY. The roles of microRNAs in the progression of castration-resistant prostate cancer. J Hum Gene. 62 (1): 25-31, 2017.
Masuda H, Kaga K, Inahara M, Araki K, Kojima S, Naya Y, Takano M.Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer. Urol Case Rep. 13: 63-5, 2017.
Arai T, Okato A, Kojima S, Idichi T, Koshizuka K, Kurozumi A, Kato M, Yamazaki K, Ishida Y, Naya Y, Ichikawa T, Seki N.Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma. Cancer Sci. 108(10): 2088-2101, 2017.
Okato A, Arai T, Yamada Y, Sugawara S, Koshizuka K, Fujimura L, Kurozumi A, Kato M, Kojima S, Naya Y, Ichikawa T, Seki N. Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma. Int J Mol Sci. 18(9), 2017.
Kamiya N., Suzuki H., Suyama T., Kobayashi M., Fukasawa S., Sekita N., Mikami K., Nihei, N. Naya N., Ichikawa T. Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study. Int J Clin Oncol. 22(2), 353-358, 2017.
Goto Y, Kojima S., Kurozumi A., Kato M., Okato A. , Matsushita R., Ichikawa T., Seki N. Regulation of E3 ubiquitin ligase-1 (WWP1)by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer. Br J Cancer. 114(10), 1135-44, 2016.
Goto, Y., S. Kojima, R. Nishikawa, A. Kurozumi, M. Kato, H. Enokida, R. Matsushita, K. Yamazaki, Y. Ishida, M. Nakagawa, Y. Naya, T. Ichikawa, and N. Seki, MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. Br J Cancer, 113(7): 1055-65, 2015.
Kanya Kaga, K.A., Kanesaka M., Sugiura M., Ho K., Masuda H., Kojima S., and Naya Y., Does Pioglitazone Increase the Risk of Bladder Cancer in Japanese Diabetic Patients? Medical & Surgical Urology, 04(01): 147-49, 2014.
Kojima, S., H. Enokida, H. Yoshino, T. Itesako, T. Chiyomaru, T. Kinoshita, M. Fuse, R. Nishikawa, Y. Goto, Y. Naya, M. Nakagawa, and N. Seki, The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet, 59(2): 78-87. 2014.
Inahara, M., M. Sugiura, K. Kaga, K. Hou, K. Araki, H. Masuda, S. Kojima, and Y. Naya, Clinical outcomes after combined therapy with dutasteride in patients with unsuccessful trial without catheter after treatment with an alpha1-adrenergic receptor blocker monotherapy for acute urinary retention caused by prostatic hyperplasia]. Nihon Hinyokika Gakkai Zasshi, 105(4): 190-5. 2014.